reversed-phase HPLC comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-03-28. Where a claim depends on a specific study, the study is described rather than over-claimed.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Findings across trials are mixed; some report changes in selected immune markers, while others find no clear clinical benefit. Many studies are small and define outcomes differently, which limits comparison. Regulatory approval is confined to a few countries, and the compound is not an approved drug in the United States or most of Europe.
Overall evidence quality varies considerably. A large share of published reports come from single centers, rely on surrogate immunological markers, or lack adequate control groups. Systematic reviews have highlighted this heterogeneity as a barrier to pooling results. Open questions include which patients, if any, might benefit, what treatment duration is appropriate, and whether any effect is independent of standard care. The peptide is often described as an immune modulator rather than a therapy for one disease, which complicates confirmatory trial design.
Lyophilized material is generally held at reduced temperature to slow degradation, and storage at minus twenty degrees Celsius or lower is common practice for long-term retention. Short-term working portions are often kept between two and eight degrees Celsius. Once dissolved, the peptide is less stable than the dry powder, and repeated freeze-thaw cycles are associated with loss of material and with aggregate formation. Vials are usually allowed to reach room temperature before opening so that condensation does not introduce moisture, and solutions are protected from light where practical.
Identity and purity are assessed mainly by reversed-phase high-performance liquid chromatography, which separates the peptide from closely related impurities and from truncated or oxidized variants. Mass spectrometry supplies the molecular mass and confirms the expected sequence length, while amino acid analysis can be used to check composition. Because the molecule has no chromophore beyond the peptide backbone, ultraviolet detection is typically performed at a low wavelength, where baseline interference from solvents and buffers is a practical concern. Water content and counter-ion content are often reported alongside purity.
Practical handling focuses on limiting adsorption and contamination. The peptide dissolves readily in water, and dilute solutions tend to adhere to plastic and glass surfaces, so an inert carrier protein or a defined buffer can reduce losses in laboratory work. Workers also record the counter-ion form, since an acetate or trifluoroacetate salt changes the mass balance of the weighed powder. Documentation of lot number, purity value, and storage history supports reproducibility when results from different laboratories are compared.
| Property | Value | Notes |
|---|---|---|
| First described | 1977 | Reported as a component of thymosin fraction 5 |
| Sequence length | 28 amino acids | N-terminal residue is acetylated |
| Net charge at neutral pH | Negative | Reflects a high proportion of acidic residues |
| Principal studied uses | Chronic hepatitis B and vaccine adjuvant | Research uses outnumber approved indications |
| Regulatory status | Approved in a limited number of countries | Not approved in the United States or most of Europe |
Thymosin alpha-1 is a synthetic peptide of 28 amino acids whose sequence matches the amino-terminal region of prothymosin alpha. The chain is acetylated at its first residue and contains one disulfide bridge between two cysteine residues, which folds the molecule into a compact loop. Its molecular formula, C129H215N33O55, corresponds to a monoisotopic mass of roughly 3,106 daltons. Material used in laboratories is made by solid-phase synthesis rather than isolated from animal tissue.
Early work on thymic extracts in the 1960s described a heat-stable acidic fraction containing many polypeptides. Separation of that mixture yielded individual components, and thymosin alpha-1 was named as one of them on the basis of assays for T-cell activity. The first preparations came from calf thymus, while subsequent research and clinical material has been chemically synthesized. Nomenclature in older papers is inconsistent, and the same peptide sometimes appears under different designations, which complicates literature searches.
Most published studies on thymosin alpha-1 report changes in immune measurements rather than clinical outcomes, and findings differ across designs and populations. Whether the peptide signals through one defined receptor or through several less specific interactions remains an open question. Its reported circulation half-life of a few hours complicates comparison of dosing schedules across trials. Mechanistic claims are frequently drawn from isolated cell cultures, and how far those results extend to whole organisms is unresolved.
Thymosin alpha 1 is a 28-amino-acid peptide first isolated from thymosin fraction 5, a bovine thymic extract. Its sequence begins with an acetylated serine residue and carries a high proportion of acidic residues, so the molecule has a net negative charge near neutral pH. Despite the shared name, it is unrelated in sequence to the thymosin beta family. Synthetic material prepared by solid-phase peptide synthesis is identical in sequence to the natural peptide.
Several names appear in the literature for this peptide, including thymalfasin and the abbreviation T-alpha-1. Naming conventions differ among research articles, regulatory documents, and supplier catalogs, which complicates literature searches. Both synthetic and recombinant production routes yield a peptide with the same 28-residue sequence as the thymic isolate. Because the thymosin label also covers unrelated peptides, sources should be compared by sequence rather than by name alone.
=== Imaging === The SBP-Tag will also bind to streptavidin or streptavidin reagents in solution. Applications of these engineered associations include the visualization of specific proteins within living cells, monitoring of the kinetics of the translation of individual proteins in an in vitro translation system, control of the integration of a multi-spanning membrane protein into the endoplasmic reticulum by fusing the SBP-Tag to the N-terminal translocation sequence and then halting integration with streptavidin and restarting integration with biotin. Fluorescent streptavidin reagents (e.g. streptavidin-HRP) can be used to visualize the SBP-tag by immunoblotting of SDS-PAGE. Additionally, antibodies to the SBP-tag are available commercially.
== External links == International Union of Pure and Applied Chemistry Archived 2007-10-31 at the Wayback Machine IUPAC Nomenclature Home Page, see especially the "Gold Book" containing definitions of standard chemical terms Interactive Mind Map of Chemistry / Chemical energetics Archived 2018-01-27 at the Wayback Machine
=== November === 1 November – The Commissioner for Ethical Standards in Public Life in Scotland finds SNP councillor Kairin van Sweeden in breach of the code of conduct for calling a political opponent a "New Scot" during a meeting of Aberdeen City Council in October 2023. 2 November – A 74-year-old man receives fatal injuries after being struck by a bus in Edinburgh's Cowgate. The following day, Police Scotland ask members of the public to stop sharing graphic images of the incident on social media. 3 November – Police Scotland say they have received a fresh allegation concerning a non-recent sexual assault against former First Minister Alex Salmond. 5 November – Senior consultants in Scotland have voted to accept a 10.5% pay rise that will see them earn between £10,500 and £13,500 extra each year, and which will be backdated to 1 April 2024. A waste management company is to sue the Scottish Government for £170m over the failed bottle return scheme. Bonfire Night disturbance breaks out in parts of Edinburgh, with missiles such as bricks, bottles and fireworks thrown at police. 6 November – Police Scotland say they have made 19 arrests following disturbances over Halloween and Bonfire Night. 8 November – The death certificate of Susan McGowan, a 58-year-old nurse from North Lanarkshire who died in September, has linked her death with the use of the weight loss drug tirzepatide (known under the brand name Mounjaro), which was recently approved for use on the NHS; it is reported to be the first UK death linked to the drug's use.
Sources: en.wikipedia.org
== Additional application == Acetoacetyl-CoA also behaves as a product of acetoacetyl-CoA synthetase (AACS) within the cytosol, using acetoacetate as the substrate, the reaction provides acetyl groups for lipogenesis. Understanding acetoacetyl-CoA is important in cholesterol development and lipogenesis and Acetoacetyl-CoA synthetase playing a role in its development, it also plays a significant role within the brain. Cholesterol and fats have been observed in high concentrations within neuronal tissue, as well as high AACS mRNA expression levels within cells of the hippocampus and cortical region. In addition, they play a significant role in neuronal development during the early embryonic and fetal developmental stages.
1993/2046) Police (Amendment) (No.3) Regulations 1993 (S.I. 1993/2047) Goods Vehicles (Plating and Testing) (Amendment) Regulations 1993 (S.I. 1993/2048) National Health Service (Travelling Expenses and Remission of Charges) (Scotland) Amendment (No.2) Regulations 1993 (S.I. 1993/2049) Prisoners and Criminal Proceedings (Scotland) Act 1993 Commencement, Transitional Provisions and Savings Order 1993 (S.I. 1993/2050) A34 Trunk Road (A34/M4 Junction 13 Improvement) Line and Slip Roads Order 1993 (S.I. 1993/2056) A6 Trunk Road (Great Glen Bypass) Order 1993 (S.I. 1993/2057) A6 Trunk Road (Great Glen Bypass) (Detrunking) Order 1993 (S.I. 1993/2058) Easington Lagoons (Area of Special Protection) (No.2) Order 1993 (S.I. 1993/2059) Capacity Serving Measures (Intoxicating Liquor) (Amendment) Regulations 1993 (S.I. 1993/2060) Enforcement of Road Traffic Debts (Certificated Bailiffs) Regulations 1993 (S.I. 1993/2072) Enforcement of Road Traffic Debts Order 1993 (S.I. 1993/2073) Education (School Performance Information) (England) (No. 2) Regulations 1993 (S.I. 1993/2077) Housing Renovation etc. Grants (Prescribed Forms and Particulars) (Welsh Forms and Particulars) (Amendment) (No. 2) Regulations 1993 (S.I. 1993/2078) Lerwick Harbour Revision Order 1993 (S.I. 1993/2087) Safety of Sports Grounds (Designation) Order 1993 (S.I. 1993/2090) Essex and Greater London (County Boundaries) Order 1993 (S.I. 1993/2091) Social Security (Contributions) Amendment (No. 6) Regulations 1993 (S.I. 1993/2094) Local Authorities (Goods and Services) (Public Bodies) Order 1993 (S.I.
=== Metabolic detoxification === An animal's metabolism can produce harmful substances which it can then make less toxic through reduction, oxidation (collectively known as redox reactions), conjugation and excretion of molecules from cells or tissues. This is called xenobiotic metabolism. Enzymes that are important in detoxification metabolism include cytochrome P450 oxidases, UDP-glucuronosyltransferases, and glutathione S-transferases. These processes are particularly well-studied as part of drug metabolism, as they influence the pharmacokinetics of a drug in the body.
Sources: en.wikipedia.org
Trials differ in patient population, dose schedule, background treatment, and the endpoints used to judge success. Many are small and single-center, so random variation can dominate the reported effects.
Authorization is limited to a small number of countries and covers specific indications such as chronic hepatitis B and vaccine adjuvant use. Availability and labelling differ by jurisdiction.
Most reviews describe it as an immunomodulatory agent with an uncertain clinical effect. They generally call for larger, better-controlled trials before firm conclusions are drawn.
Cool storage below freezing is usual for long-term retention, with a desiccant and protection from light. Portions are often split before first use to avoid repeated handling.